Abbott Laboratories (ABT)
NYSE • Healthcare
November 20, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Abbott Laboratories keeps $7 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Jan 28
in 67 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Abbott Laboratories’ revenue rose 14.5% to about $13.0 billion in the third fiscal quarter of 2026 (period ended September 30, 2026), with results reported October 21, 2026 based on preliminary figures; adjusted EPS of $1.42 came in line with the $1.42 estimate, and revenue of $13.013 billion was in line with the $12.989 billion estimate (+0.2%). The top line was up from about $11.4 billion a year ago, while profitability showed gross margin at roughly 57% and operating margin near 11% as gross profit was about $7.4 billion and operating income around $1.5 billion across the company’s mix of medical devices, diagnostics, nutrition, and established pharmaceuticals. Net income fell 44.0% year over year to roughly $920 million, down from about $1.6 billion a year ago, even as adjusted EPS increased 9.2% from $1.30. For the next period, consensus calls for EPS of $1.65 on revenue of $13.257 billion.
About Abbott Laboratories
Abbott Laboratories (NYSE: ABT) is a healthcare company centered on medical devices, diagnostics, nutrition, and branded generic medications sold through worldwide distribution, with operations that reach global markets. Across these businesses, Abbott generated $44.3 billion of revenue in FY2025, spanning products used in testing, chronic disease management, and everyday nutritional care.
Today's Snapshot
ABT closed 0.7% below yesterday's close, while its sector was flat. Volume was about two-thirds of its usual level. Leerink, a stock research firm, upgraded Abbott Laboratories to Outperform.
Trading Volume
Below 10d avg (7.5M)
5.1M
vs S&P 500 Today
Outperforming Market
+2.84%
Updated: November 20, 2026 at 21:09 UTC
ABT Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$104.25 - $106.33Sell
- RSI (14)41.89Neutral
- Stochastic %K (14, 3, 3)4.88Buy
- MACD Level (12, 26)0.11Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.